Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Hormone therapy and sarcopenia: implications for the prevention of frailty as women age.

Kaunitz AM, Pinkerton JV, Manson JE.

Menopause. 2020 Mar 16. doi: 10.1097/GME.0000000000001541. [Epub ahead of print] No abstract available.

PMID:
32187132
2.

Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma.

Ali MK, Kim RY, Brown AC, Mayall JR, Karim R, Pinkerton JW, Liu G, Martin KL, Starkey MR, Pillar A, Donovan C, Pathinayake PS, Carroll OR, Trinder D, Tay HL, Badi YE, Kermani NZ, Guo YK, Aryal R, Mumby S, Pavlidis S, Adcock IM, Weaver J, Xenaki D, Oliver BG, Holliday EG, Foster PS, Wark PA, Johnstone DM, Milward EA, Hansbro PM, Horvat JC.

Eur Respir J. 2020 Mar 17. pii: 1901340. doi: 10.1183/13993003.01340-2019. [Epub ahead of print]

PMID:
32184317
3.

Response to Letter to the Editor: "Global Consensus Position Statement on the Use of Testosterone Therapy for Women".

Davis SR, Baber R, Panay N, Pinkerton J.

J Clin Endocrinol Metab. 2020 Jun 1;105(6). pii: dgaa126. doi: 10.1210/clinem/dgaa126. No abstract available.

PMID:
32160277
4.

Critical role for iron accumulation in the pathogenesis of fibrotic lung disease.

Ali MK, Kim RY, Brown AC, Donovan C, Vanka KS, Mayall JR, Liu G, Pillar AL, Jones-Freeman B, Xenaki D, Borghuis T, Karim R, Pinkerton JW, Aryal R, Heidari M, Martin KL, Burgess JK, Oliver BG, Trinder D, Johnstone DM, Milward EA, Hansbro PM, Horvat JC.

J Pathol. 2020 Feb 21. doi: 10.1002/path.5401. [Epub ahead of print]

PMID:
32083318
5.

fastMRI: A Publicly Available Raw k-Space and DICOM Dataset of Knee Images for Accelerated MR Image Reconstruction Using Machine Learning.

Knoll F, Zbontar J, Sriram A, Muckley MJ, Bruno M, Defazio A, Parente M, Geras KJ, Katsnelson J, Chandarana H, Zhang Z, Drozdzalv M, Romero A, Rabbat M, Vincent P, Pinkerton J, Wang D, Yakubova N, Owens E, Zitnick CL, Recht MP, Sodickson DK, Lui YW.

Radiol Artif Intell. 2020 Jan 29;2(1):e190007. doi: 10.1148/ryai.2020190007.

6.

Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society.

Sinno AK, Pinkerton J, Febbraro T, Jones N, Khanna N, Temkin S, Iglesias D, Pothuri B.

Gynecol Oncol. 2020 Feb 15. pii: S0090-8258(20)30088-3. doi: 10.1016/j.ygyno.2020.01.035. [Epub ahead of print] No abstract available.

PMID:
32067815
7.

Underlying breast cancer risk and menopausal hormone therapy.

Santen RJ, Heitjan DF, Gompel A, Lumsden MA, Pinkerton JV, Davis SR, Stuenkel CA.

J Clin Endocrinol Metab. 2020 Feb 13. pii: dgaa073. doi: 10.1210/clinem/dgaa073. [Epub ahead of print]

PMID:
32052007
8.

Hormone Therapy for Postmenopausal Women.

Pinkerton JV.

N Engl J Med. 2020 Jan 30;382(5):446-455. doi: 10.1056/NEJMcp1714787. Review. No abstract available.

PMID:
31995690
9.

Management of Menopause and the Role For Hormone Therapy.

Pinkerton JV, Conner EA, Kaunitz AM.

Clin Obstet Gynecol. 2019 Dec;62(4):677-686. doi: 10.1097/GRF.0000000000000487.

PMID:
31503029
10.

Global Consensus Position Statement on the Use of Testosterone Therapy for Women.

Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME.

J Clin Endocrinol Metab. 2019 Oct 1;104(10):4660-4666. doi: 10.1210/jc.2019-01603.

11.

Global Consensus Position Statement on the Use of Testosterone Therapy for Women.

Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME.

J Sex Med. 2019 Sep;16(9):1331-1337. doi: 10.1016/j.jsxm.2019.07.012.

PMID:
31488288
12.

Global Consensus Position Statement on the use of Testosterone Therapy for Women.

Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME.

Maturitas. 2019 Oct;128:89-93. doi: 10.1016/j.maturitas.2019.07.001. Epub 2019 Sep 1. No abstract available.

PMID:
31484631
13.

Global Consensus Position Statement on the Use of Testosterone Therapy for Women.

Davis SR, Baber R, Panay N, Bitzer J, Cerdas Perez S, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME.

Climacteric. 2019 Oct;22(5):429-434. doi: 10.1080/13697137.2019.1637079. Epub 2019 Sep 2. No abstract available. Erratum in: Climacteric. 2019 Dec;22(6):637.

PMID:
31474158
14.

Managing vasomotor symptoms in women after cancer.

Pinkerton JV, Santen RJ.

Climacteric. 2019 Dec;22(6):544-552. doi: 10.1080/13697137.2019.1600501. Epub 2019 May 13.

PMID:
31081391
15.

Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators.

Pinkerton JV, Conner EA.

Climacteric. 2019 Apr;22(2):140-147. doi: 10.1080/13697137.2019.1568403.

PMID:
30895900
16.

Women harmed by vaginal laser for treatment of GSM-the latest casualties of fear and confusion surrounding hormone therapy.

Kaunitz AM, Pinkerton JV, Manson JE.

Menopause. 2019 Apr;26(4):338-340. doi: 10.1097/GME.0000000000001313. No abstract available.

17.

Female Sexual Health: Barriers to Optimal Outcomes and a Roadmap for Improved Patient-Clinician Communications.

Kingsberg SA, Schaffir J, Faught BM, Pinkerton JV, Parish SJ, Iglesia CB, Gudeman J, Krop J, Simon JA.

J Womens Health (Larchmt). 2019 Apr;28(4):432-443. doi: 10.1089/jwh.2018.7352. Epub 2019 Feb 4.

18.

Assessment of NAMS members' prescription patterns of hormone therapy before and after the 2016 NAMS Annual Meeting.

Bonnett LP, Jiang X, Pinkerton JV, Schnatz PF.

Menopause. 2019 Mar;26(3):240-247. doi: 10.1097/GME.0000000000001201.

PMID:
30399025
19.

Hormone therapy does not impact long-term all-cause mortality.

Pinkerton JV.

BJOG. 2019 Jan;126(1):64. doi: 10.1111/1471-0528.15480. Epub 2018 Oct 24. No abstract available.

20.

Vaginal estrogen: Underprescribed treatment for an underdiagnosed condition of menopausal women.

Kaunitz AM, Pinkerton JV, Manson JE.

Maturitas. 2019 Mar;121:83-85. doi: 10.1016/j.maturitas.2018.08.001. Epub 2018 Aug 4. No abstract available.

PMID:
30098845
21.

Why Should Clinicians Be Concerned About Prescribing Compounded Hormones for Menopausal Women?

Pinkerton JV.

J Womens Health (Larchmt). 2018 Jul;27(7):847-849. doi: 10.1089/jwh.2018.7215. Epub 2018 Jun 29. No abstract available.

PMID:
29957102
22.

Not time to abandon use of local vaginal hormone therapies.

Pinkerton JV, Kaunitz AM, Manson JE.

Menopause. 2018 Aug;25(8):855-858. doi: 10.1097/GME.0000000000001142. No abstract available.

PMID:
29894370
23.

Hormone Therapy: Key Points From NAMS 2017 Position Statement.

Pinkerton JV.

Clin Obstet Gynecol. 2018 Sep;61(3):447-453. doi: 10.1097/GRF.0000000000000383. Review.

PMID:
29889667
24.

Foreword: Managing Menopause by Combining Evidence With Clinical Judgment.

Kaunitz AM, Pinkerton JV.

Clin Obstet Gynecol. 2018 Sep;61(3):417-418. doi: 10.1097/GRF.0000000000000387. No abstract available.

PMID:
29889666
25.

The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.

Simon JA, Goldstein I, Kim NN, Davis SR, Kellogg-Spadt S, Lowenstein L, Pinkerton JV, Stuenkel CA, Traish AM, Archer DF, Bachmann G, Goldstein AT, Nappi RE, Vignozzi L.

Menopause. 2018 Jul;25(7):837-847. doi: 10.1097/GME.0000000000001138.

PMID:
29870471
26.

Tissue-selective Estrogen Complex for Menopausal Hormone Therapy.

Pinkerton JV.

Clin Obstet Gynecol. 2018 Sep;61(3):463-469. doi: 10.1097/GRF.0000000000000386. Review.

PMID:
29851863
27.

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health.

Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, Kaunitz AM, Krychman ML, Parish SJ, Partridge AH, Pinkerton JV, Rowen TS, Shapiro M, Simon JA, Goldfarb SB, Kingsberg SA.

Menopause. 2018 Jun;25(6):596-608. doi: 10.1097/GME.0000000000001121.

PMID:
29762200
28.

Concern about US Preventive Services Task Force recommendation on hormone therapy for the primary prevention of chronic conditions in postmenopausal women.

Pinkerton JV, Kaunitz AM, Manson JE.

Menopause. 2018 May;25(5):476. doi: 10.1097/GME.0000000000001100. No abstract available.

PMID:
29658911
29.

Hormonal contraception and risk of breast cancer: a closer look.

Kaunitz AM, Pinkerton JV, Manson JE.

Menopause. 2018 May;25(5):477-479. doi: 10.1097/GME.0000000000001101. No abstract available.

PMID:
29557848
30.

Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis.

Pinkerton JV, James AH.

Clin Obstet Gynecol. 2018 Jun;61(2):260-268. doi: 10.1097/GRF.0000000000000358. Review.

PMID:
29419532
31.

Screening mammography for average-risk women.

Kaunitz AM, Pinkerton JV, Ghate SV, Wolf AMD.

Menopause. 2018 Mar;25(3):343-345. doi: 10.1097/GME.0000000000001026. Review.

PMID:
29257034
32.

Menopause 25th anniversary: past success and future direction.

Schiff I, Utian WH, Pinkerton JV.

Menopause. 2018 Jan;25(1):1-3. doi: 10.1097/GME.0000000000001038. No abstract available.

PMID:
29251683
33.

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.

Simon JA, Altomare C, Cort S, Jiang W, Pinkerton JV.

J Womens Health (Larchmt). 2018 Jan;27(1):14-23. doi: 10.1089/jwh.2017.6385. Epub 2017 Oct 24.

34.

Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance.

Pinkerton JV, Kaunitz AM, Manson JE.

Menopause. 2017 Dec;24(12):1329-1332. doi: 10.1097/GME.0000000000000996. Review. No abstract available.

PMID:
29040220
35.

Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors.

Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA.

J Clin Endocrinol Metab. 2017 Oct 1;102(10):3647-3661. doi: 10.1210/jc.2017-01138. Review.

PMID:
28934376
36.

Changing the conversation about hormone therapy.

Pinkerton JV.

Menopause. 2017 Sep;24(9):991-993. doi: 10.1097/GME.0000000000000965. No abstract available.

PMID:
28763394
37.

Changing the conversation about hormone therapy.

Pinkerton JV.

Climacteric. 2017 Aug;20(4):293-295. doi: 10.1080/13697137.2017.1346380. Epub 2017 Jul 4. No abstract available.

PMID:
28675703
38.

Safety and benefit considerations for menopausal hormone therapy.

Pickar JH, Archer DF, Kagan R, Pinkerton JV, Taylor HS.

Expert Opin Drug Saf. 2017 Aug;16(8):941-954. doi: 10.1080/14740338.2017.1343298. Epub 2017 Jun 30. Review.

PMID:
28664754
39.

Hot flush frequency and severity at baseline as predictors of time to transient and stable treatment success: pooled analysis of two CE/BZA studies.

Pinkerton JV, Bushmakin AG, Bobula J, Lavenberg J, Komm BS, Abraham L.

Menopause. 2017 Dec;24(12):1378-1385. doi: 10.1097/GME.0000000000000918.

PMID:
28654628
40.

Time to first occurrence of breast pain and vaginal bleeding in phase 3 trials of CE/BZA.

Pinkerton JV, Bushmakin AG, Bobula J, Lavenberg J, Komm BS, Abraham L.

Menopause. 2017 Dec;24(12):1372-1377. doi: 10.1097/GME.0000000000000935.

PMID:
28609389
41.

Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.

Pinkerton JV, Bushmakin AG, Komm BS, Abraham L.

Maturitas. 2017 Jun;100:57-63. doi: 10.1016/j.maturitas.2017.03.315. Epub 2017 Mar 22.

PMID:
28539177
42.

Time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene.

Pinkerton JV, Bushmakin AG, Abraham L, Komm BS, Bobula J.

Menopause. 2017 Sep;24(9):1011-1016. doi: 10.1097/GME.0000000000000888.

PMID:
28463874
43.

Role for NLRP3 Inflammasome-mediated, IL-1β-Dependent Responses in Severe, Steroid-Resistant Asthma.

Kim RY, Pinkerton JW, Essilfie AT, Robertson AAB, Baines KJ, Brown AC, Mayall JR, Ali MK, Starkey MR, Hansbro NG, Hirota JA, Wood LG, Simpson JL, Knight DA, Wark PA, Gibson PG, O'Neill LAJ, Cooper MA, Horvat JC, Hansbro PM.

Am J Respir Crit Care Med. 2017 Aug 1;196(3):283-297. doi: 10.1164/rccm.201609-1830OC.

PMID:
28252317
44.

Inflammasomes in the lung.

Pinkerton JW, Kim RY, Robertson AAB, Hirota JA, Wood LG, Knight DA, Cooper MA, O'Neill LAJ, Horvat JC, Hansbro PM.

Mol Immunol. 2017 Jun;86:44-55. doi: 10.1016/j.molimm.2017.01.014. Epub 2017 Jan 24. Review.

PMID:
28129896
45.

Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.

Abraham L, Bushmakin AG, Dragon E, Komm BS, Pinkerton JV.

Maturitas. 2016 Dec;94:173-179. doi: 10.1016/j.maturitas.2016.09.010. Epub 2016 Sep 16.

PMID:
27823739
46.

Timing and persistence of effect of conjugated estrogens/bazedoxifene in postmenopausal women.

Kagan R, Komm BS, Ryan KA, Lavenberg J, Yu CR, Pinkerton JV.

Menopause. 2016 Nov;23(11):1204-1213.

PMID:
27433860
47.

Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.

Archer DF, Freeman EW, Komm BS, Ryan KA, Yu CR, Mirkin S, Pinkerton JV.

J Womens Health (Larchmt). 2016 Nov;25(11):1102-1111. Epub 2016 Sep 27.

PMID:
27676118
48.

Elucidating novel disease mechanisms in severe asthma.

Kim RY, Rae B, Neal R, Donovan C, Pinkerton J, Balachandran L, Starkey MR, Knight DA, Horvat JC, Hansbro PM.

Clin Transl Immunology. 2016 Jul 15;5(7):e91. doi: 10.1038/cti.2016.37. eCollection 2016 Jul. Review.

49.

MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2.

Kim RY, Horvat JC, Pinkerton JW, Starkey MR, Essilfie AT, Mayall JR, Nair PM, Hansbro NG, Jones B, Haw TJ, Sunkara KP, Nguyen TH, Jarnicki AG, Keely S, Mattes J, Adcock IM, Foster PS, Hansbro PM.

J Allergy Clin Immunol. 2017 Feb;139(2):519-532. doi: 10.1016/j.jaci.2016.04.038. Epub 2016 Jun 10.

50.

Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters.

Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Komm BS.

Menopause. 2016 Oct;23(10):1060-6. doi: 10.1097/GME.0000000000000678.

PMID:
27404028

Supplemental Content

Loading ...
Support Center